Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) shares fell 3.5% during mid-day trading on Monday . The company traded as low as $7.71 and last traded at $7.75, with a volume of 74,221 shares changing hands. The stock had previously closed at $8.03.

A number of research analysts recently issued reports on ADAP shares. Zacks Investment Research raised Adaptimmune Therapeutics PLC – from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a report on Tuesday, July 12th. Leerink Swann reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a report on Sunday, April 24th. Six investment analysts have rated the stock with a buy rating, Adaptimmune Therapeutics PLC – presently has an average rating of “Buy” and an average target price of $15.94.

The stock’s market capitalization is $552.12 million. The company has a 50 day moving average price of $9.20 and a 200 day moving average price of $8.87.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.03. Equities research analysts anticipate that Adaptimmune Therapeutics PLC – will post ($1.12) EPS for the current year.

In other Adaptimmune Therapeutics PLC – news, Director Charles Elliott Sigal purchased 45,000 shares of the stock in a transaction on Wednesday, May 18th. The shares were bought at an average cost of $1.53 per share, with a total value of $68,850.00. Following the completion of the acquisition, the director now owns 52,938 shares in the company, valued at $80,995.14. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Orbimed Advisors Llc purchased 1,712,400 shares of the stock in a transaction on Tuesday, May 24th. The stock was acquired at an average cost of $10.42 per share, for a total transaction of $17,843,208.00. The disclosure for this purchase can be found here.

A number of large investors have bought and sold shares of the stock. Marshall Wace LLP acquired a new stake in Adaptimmune Therapeutics PLC – during the fourth quarter valued at approximately $1,700,000. Tekla Capital Management LLC raised its stake in Adaptimmune Therapeutics PLC – by 5.3% in the fourth quarter. Tekla Capital Management LLC now owns 296,934 shares of the company’s stock valued at $3,581,000 after buying an additional 15,000 shares during the last quarter. Finally, Jennison Associates LLC raised its stake in Adaptimmune Therapeutics PLC – by 0.3% in the fourth quarter. Jennison Associates LLC now owns 486,948 shares of the company’s stock valued at $5,873,000 after buying an additional 1,547 shares during the last quarter.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.